Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis

Authors :: Yi-Long Wu
Andreas Johne
Rolf Bruns
Karin Berghoff
Jun Zhao
Yiping Zhang
James Chih-Hsin Yang
Sang Won Shin
Shun Lu
Ying Cheng
Ross Andrew Soo
Dong-Wan Kim
Jianying Zhou
Te-Chun Hsia
Azura Rozila Ahmad
Chong Kin Liam
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Treatment-related adverse events in treated patients with MET amplification and/or MET IHC 2+/3+

Full Text Access

Tools